Search IPOs
Subscription Status · May 12 – May 14, 2026 · ₹41–43
The Goldline Pharmaceutical IPO subscription has recorded exceptional investor demand with an overall subscription of 840.74× as of May 14, 2026, indicating that investors applied for 840.74 times the number of shares on offer. All investor categories (institutional, HNI, and retail) have participated actively, making this one of the closely watched IPO openings.
Last updated: May 14, 2026, 5:17 PM IST
| Category | Shares Offered | Shares Bid For | Times Subscribed | Applications |
|---|---|---|---|---|
|
QIB
Qualified Institutional Buyers
|
540,000 | 97,317,000 |
180.22×
|
- |
|
NII
Non-Institutional Investors
|
390,000 | 648,195,000 |
1,662.04×
|
- |
|
bNII
Bids above ₹10L
|
260,000 | 518,736,000 |
1,995.14×
|
- |
|
sNII
Bids below ₹10L
|
130,000 | 129,459,000 |
995.84×
|
- |
|
Individual
Individual Investors
|
900,000 | 793,038,000 |
881.15×
|
- |
|
Total
|
1,830,000 | 1,538,550,000 |
840.74×
|
- |
How subscription built up across investor categories over time
Snapshot of each day's bidding activity
| Category | Offered | Bid For | Times | Applications |
|---|---|---|---|---|
| QIB | 540,000 | 705,000 | 1.31× | - |
| NII | 390,000 | 9,540,000 | 24.46× | - |
| bNII | 260,000 | 5,811,000 | 22.35× | - |
| sNII | 130,000 | 3,729,000 | 28.68× | - |
| Individual Investors | 900,000 | 30,432,000 | 33.81× | - |
| Total | 1,830,000 | 40,677,000 | 22.23× | - |
| Category | Offered | Bid For | Times | Applications |
|---|---|---|---|---|
| QIB | 540,000 | 705,000 | 1.31× | - |
| NII | 390,000 | 56,988,000 | 146.12× | - |
| bNII | 260,000 | 41,277,000 | 158.76× | - |
| sNII | 130,000 | 15,711,000 | 120.85× | - |
| Individual Investors | 900,000 | 125,562,000 | 139.51× | - |
| Total | 1,830,000 | 183,255,000 | 100.14× | - |
| Category | Offered | Bid For | Times | Applications |
|---|---|---|---|---|
| QIB | 540,000 | 97,317,000 | 180.22× | - |
| NII | 390,000 | 648,195,000 | 1,662.04× | - |
| bNII | 260,000 | 518,736,000 | 1,995.14× | - |
| sNII | 130,000 | 129,459,000 | 995.84× | - |
| Individual Investors | 900,000 | 793,038,000 | 881.15× | - |
| Total | 1,830,000 | 1,538,550,000 | 840.74× | - |
As of May 14, 2026, the Goldline Pharmaceutical IPO has been subscribed 840.74 times overall. The IPO is fully subscribed with strong investor demand indicating extremely high interest.
The Goldline Pharmaceutical IPO subscription window was open from May 12, 2026 to May 14, 2026. Investors could apply through their demat account or ASBA facility.
The Goldline Pharmaceutical IPO has a price band of ₹41 to ₹43 per share, with a lot size of 3,000 shares. Minimum retail investment: ₹123,000 (lower band) or ₹129,000 (upper band).
The QIB category has been subscribed 180.22 times. QIBs were offered 540,000 shares. Strong QIB subscription indicates high institutional confidence.
Overall NII: 1,662.04×. bNII (>₹10L): 1,995.14×, sNII (<₹10L): 995.84×. NII includes HNIs and corporate entities investing above ₹2 lakh.
Basis of allotment is on May 15, 2026. Check via the registrar's website, Bigshare Services Private Limited using your PAN number, application number, or DP/Client ID. You can also check on BSE/NSE websites or through your broker's app.
Goldline Pharmaceutical IPO is expected to list on May 19, 2026. Shares will list on BSE SME platform. Allotted shares are credited to your demat account 1 business day before listing.
A subscription multiple of 840.74× means investors have bid for 840.74 times the total shares available. Since the IPO is oversubscribed, not every applicant will receive shares, allotment happens via lottery (for retail) or proportionately (for other categories). Higher multiples generally reduce allotment probability.
Based on the current retail subscription of data pending, the estimated allotment probability for retail investors is Very Low. Only 1 lot likely via lottery if selected. If final subscription stays below 1×, all applicants are likely to get full allotment.
You can apply for Goldline Pharmaceutical IPO through: (1) ASBA (Application Supported by Blocked Amount) via your bank's net banking or mobile app, (2) UPI-based application through your broker's app (Zerodha, Groww, Angel One, etc.), or (3) directly via your demat account. The amount is blocked in your account and deducted only upon allotment. Applications were accepted from May 12 to May 14, 2026.
The grey market premium (GMP) reflects unofficial pre-listing trading sentiment. For the latest Goldline Pharmaceutical IPO GMP data, check the IPORise GMP page. Note: GMP is unofficial, speculative, and not a guaranteed indicator of listing price. Use it only as a sentiment signal alongside official subscription data.
New to reading subscription numbers? Read our guide on IPO subscription explained.
Subscription Opens Done
May 12, 2026Subscription Closes Done
May 14, 2026Basis of Allotment Done
May 15, 2026Listing on BSE Done
May 19, 2026Only 1 lot likely via lottery if selected.
Share Subscription Card
Download a branded image to share on WhatsApp, Twitter, or Telegram
Higher subscription = lower allotment probability. Progress bars compare each category relative to the highest-subscribed category.
